Dov Pekelman replaces Hasmukh Shah on Taro's board
This article was originally published in Scrip
Taro Pharmaceutical Industries, an Israel-based multinational pharmaceutical company developing a range of generic and branded drugs, has appointed Professor Dov Pekelman to its board until the next AGM of shareholders, to fill the vacancy left by Hasmukh Shah who has resigned from the board after one year's service for personal reasons. Professor Pekelman is currently chairman of Atera Networks and Gilon Investmments.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.